RESUMEN
In recent years, diphenidol [1,1-diphenyl-4-piperidino-1-butanol] has been one of the drugs that appears in suicide cases, but there are few research data on its metabolic pathways and main metabolites. Metabolite identification plays a key role in drug safety assessment and clinical application. In this study, in vivo and in vitro samples were analyzed with ultra-high-performance liquid chromatography-quadrupole/electrostatic field orbitrap high-resolution mass spectrometry. Structural elucidation of the metabolites was performed by comparing their molecular weights and product ions with those of the parent drug. As a result, 10 Phase I metabolites and 5 glucuronated Phase II metabolites were found in a blood sample and a urine sample from authentic cases. Three other Phase I metabolites were identified in the rat liver microsomes incubation solution. The results showed that the main metabolic pathways of diphenidol in the human body include hydroxylation, oxidation, dehydration, N-dealkylation, methylation, and conjugation with glucuronic acid. This study preliminarily clarified the metabolic pathways and main metabolites of diphenidol. For the development of new methods for the identification of diphenidol consumption, we recommend using M2-2 as a marker of diphenidol entering the body. The results of this study provide a theoretical basis for the pharmacokinetics and forensic scientific research of diphenidol.
Asunto(s)
Antieméticos/metabolismo , Cromatografía Líquida de Alta Presión/métodos , Espectrometría de Masas/métodos , Piperidinas/metabolismo , Animales , Antieméticos/análisis , Humanos , Masculino , Microsomas Hepáticos/metabolismo , Piperidinas/análisis , Ratas , Ratas Sprague-Dawley , Especificidad de la EspecieRESUMEN
Background: A combination of methylprednisolone sodium succinate and tropisetron hydrochloride is commonly used to treat the nausea and vomiting associated with antineoplastic therapy. The objective of this study was to investigate the stability of tropisetron hydrochloride and methylprednisolone sodium succinate in 0.9% sodium chloride injection for up to 48 hours. Methods: Commercial solutions of methylprednisolone sodium succinate and tropisetron hydrochloride were obtained and further diluted with 0.9% sodium chloride injection to final concentrations of either 0.4 or 0.8 mg/mL (methylprednisolone sodium succinate) and 0.05 mg/mL (tropisetron). The admixtures were assessed for periods of up to 48 hours after storage at 4°C with protection from light and at 25°C without protection from light. Physical compatibility was determined visually, and the chemical compatibility was measured with high-performance liquid chromatography (HPLC) and by measurement of pH values. Results: HPLC analysis demonstrated that methylprednisolone sodium succinate and tropisetron hydrochloride in the various solutions were maintained at 97% of the initial concentrations or higher during the testing period. There were no changes observed by physical precipitation or pH in any of the prepared solutions. Conclusions: Tropisetron hydrochloride injection and methylprednisolone sodium succinate injection in 0.9% sodium chloride injection are stable for up to 48 hours at 4°C and 25°C.
Asunto(s)
Antiinflamatorios/química , Antieméticos/química , Incompatibilidad de Medicamentos , Hemisuccinato de Metilprednisolona/química , Solución Salina/química , Tropisetrón/química , Antiinflamatorios/administración & dosificación , Antiinflamatorios/análisis , Antieméticos/administración & dosificación , Antieméticos/análisis , Cromatografía Líquida de Alta Presión/métodos , Estabilidad de Medicamentos , Humanos , Inyecciones , Hemisuccinato de Metilprednisolona/administración & dosificación , Hemisuccinato de Metilprednisolona/análisis , Solución Salina/administración & dosificación , Solución Salina/análisis , Tropisetrón/administración & dosificación , Tropisetrón/análisisRESUMEN
Background and objective: Infusion containing paracetamol, alizapride, ketorolac and tramadol is used after a general anaesthesia in order to limit pain, fever and nausea. Currently, these infusions are prepared according to demand in the anaesthesia unit, but the preparation in advance could improve quality of preparation and time management. The aim of this study was to investigate the long-term stability of this infusion in glass bottles at 5°C ± 3 °C. Method: Five bottles of infusion were stored at 5°C ± 3 °C for 60 days. A visual and microscope inspection were performed periodically to observe any particle appearance or colour change. pH and absorbance at three wavelengths were measured. The concentrations were measured by ultra-high performance liquid chromatography - diode array detection. Results: Multiple verifications were performed during the first 35 days and no crystal, impurity or colour change were observed. At the next time point (42nd day), crystals were visible to the naked eye. pH and absorbance at 350 nm and 550 nm were stable. A slight increase in the absorbance at 410 nm was observed during the study, suggesting that a degradation product could be formed and absorb at this wavelength. The infusion was considered chemically stable while the lower one-sided prediction limit at 95% remains superior to 90% of the initial concentration. Concentration measurements demonstrated that ketorolac and alizapride remained stable in the infusion for 35 days. The stability of tramadol was 28 days. However, degradation of paracetamol was much faster given that concentration has fallen below 90% of the initial concentration after 7 days. Conclusion: Infusion of paracetamol, alizapride, ketorolac and tramadol remains stable for 7 days in glass bottles at 5°C ± 3 °C and could be prepared in advance with these storage conditions.
Asunto(s)
Acetaminofén/química , Embalaje de Medicamentos/normas , Vidrio/química , Ketorolaco/química , Pirrolidinas/química , Tramadol/química , Acetaminofén/administración & dosificación , Acetaminofén/análisis , Analgésicos no Narcóticos/administración & dosificación , Analgésicos no Narcóticos/análisis , Analgésicos no Narcóticos/química , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/análisis , Analgésicos Opioides/química , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/análisis , Antiinflamatorios no Esteroideos/química , Antieméticos/administración & dosificación , Antieméticos/análisis , Antieméticos/química , Embalaje de Medicamentos/métodos , Estabilidad de Medicamentos , Almacenaje de Medicamentos/métodos , Almacenaje de Medicamentos/normas , Vidrio/análisis , Vidrio/normas , Humanos , Infusiones Intravenosas , Ketorolaco/administración & dosificación , Ketorolaco/análisis , Soluciones Farmacéuticas/administración & dosificación , Soluciones Farmacéuticas/análisis , Soluciones Farmacéuticas/química , Pirrolidinas/administración & dosificación , Pirrolidinas/análisis , Factores de Tiempo , Tramadol/administración & dosificación , Tramadol/análisisRESUMEN
The manuscript describes two fluorimetric methods for the determination of some antiemetic drugs namely granisetron HCl, ondansetron HCl and tropisetron HCl, used in the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Granisetron HCl solution exhibits a native fluorescence, which can be applied for its determination at 365 nm upon excitation at 305 nm. The method was applied for the determination of granisetron HCl in drug substance, drug product as well as in presence of its acid induced degradation products. The quantum yield was calculated. The second proposed method is based on measuring the quenching effect induced by ondansetron HCl or tropisetron HCl on the fluorescence intensity of cerrous ammonium sulphate at λem 348 nm upon excitation at 250 nm in acidic medium. The analysis of quenching data showed that quenching of cerrous ammonium sulphate induced by ondansetron HCl or tropisetron HCl is mainly through dynamic quenching. Various variables affecting fluorescence response were studied and optimized. The obtained results were found to be statistically agreed with those obtained from the official or reported ones. Moreover, the validity of the methods was assessed according to ICH guidelines.
Asunto(s)
Sulfato de Amonio/análisis , Antieméticos/análisis , Granisetrón/farmacología , Ondansetrón/química , Espectrometría de Fluorescencia/métodos , Tropisetrón/química , Química Farmacéutica/métodos , Fluorometría , Hidrólisis , Teoría Cuántica , Radioterapia , Reproducibilidad de los ResultadosRESUMEN
High-resolution solid-state analysis of multicomponent molecular systems, e.g., pharmaceutical formulations, is a great challenge. Solid-state nuclear magnetic resonance (ssNMR) spectroscopy plays a critical role in the characterization of solid dosage forms due to its capabilities of chemical identification, quantification, and structural elucidation at a molecular level. However, the low NMR sensitivity as well as the high spectral complexity and low drug loading of multicomponent products hinder an in-depth investigation of the active pharmaceutical ingredient (API) at the natural isotopic abundance. Herein, we developed two new three-dimensional (3D) ssNMR methods, including 1H-19F-1H and 19F-19F-1H correlations and successfully applied them to characterize a fluorinated drug molecule, aprepitant, and its commercial nanoparticulate formulation EMEND (Merck & Co, Inc., Kenilworth, NJ, USA). These 1H-detection methods utilize the significantly enhanced sensitivity and resolution of 1H and 19F afforded by 60 kHz ultrafast magic angle spinning (MAS) and enable the analysis of milligram samples. The 3D techniques simultaneously provide homonuclear 1H-1H and 19F-19F, and heteronuclear 1H-19F correlations of the crystalline aprepitant without interferences from other pharmaceutical components in the drug product. Moreover, our results demonstrate that 19F is a highly sensitive spin for probing molecular details of fluorinated drug substances in solid formulations, due to its high isotopic abundance, large gyromagnetic ratio, and absence of signal interference from pharmaceutical excipients, as well as for characterizing structural properties of a broad range of fluorine-containing materials.
Asunto(s)
Antieméticos/análisis , Aprepitant/análisis , Hidrocarburos Fluorados/análisis , Composición de Medicamentos , Halogenación , Espectroscopía de Resonancia Magnética , Conformación MolecularRESUMEN
Untargeted toxicological screening is an analytical challenge, given the high number of molecules and metabolites to be detected and the constant appearance of new psychoactive substances (NPS). The combination of liquid chromatography with high-resolution tandem mass spectrometry (HRMS/MS) in a data-dependent acquisition mode generates a large volume of high quality spectral data. Commercial software for processing MS data acquired during untargeted screening experiments usually compare measured features (mass, retention time, and fragmentation spectra) against a predefined list of analytes. However, there is a lack of tools for visualizing and organizing MS data of unknown compounds. Here, we applied molecular networking to untargeted toxicological screening. This bioinformatic tool allows the exploration and organization of MS/MS data without prior knowledge of the sample's chemical composition. The organization of spectral data is based on spectral similarity. Hence, important information can be obtained even before the annotation step. The link established between molecules enables the propagation of structural information. We applied this approach to three clinical and forensic cases with various matrices: (a) blood and a syringe content in a forensic case of death by self-injection, (b) hair segments in a case of drug-facilitated assault, and (c) urine and blood samples in a case of 3-methoxyphencyclidine intoxication. Data preprocessing with MZmine allows sample-to-sample comparison and generation of multisample molecular networks. Our present study shows that molecular networking can be a useful complement to conventional approaches for untargeted screening interpretation, for example for xenobiotics identification or NPS metabolism elucidation.
Asunto(s)
Clormequat/análisis , Drogas de Diseño/análisis , Doxilamina/análisis , Toxicología Forense/métodos , Fenciclidina/análogos & derivados , Adolescente , Antieméticos/análisis , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fenciclidina/análisis , Espectrometría de Masas en Tándem/métodos , Adulto JovenRESUMEN
The present study involved segmental testing of hair in two clinical cases with known dosage histories. Hair analysis confirmed the first patient's exposure to the prescribed sertraline and citalopram for several months. Citalopram was generally distributed along the hair shaft in accordance with the drug ingestion period. By contrast, "false" positive results were observed for sertraline in distal hair segments, corresponding to a period of no sertraline exposure, which may indicate incorporation from sweat or sebum, which transport the drugs along the hair surface. The second patient received various drugs during her treatment for brain cancer. Metoclopramide, morphine, oxazepam, paracetamol, sumatriptan, tramadol, and zopiclone, which had been part of the therapy, were all detected in the proximal hair segment. The results of these two cases indicated that results-especially concerning the time of drug intake-must be interpreted with caution and allow for the possibility of incorporation from sweat or sebum.
Asunto(s)
Analgésicos/análisis , Cabello/química , Hipnóticos y Sedantes/análisis , Inhibidores Selectivos de la Recaptación de Serotonina/análisis , Vasoconstrictores/análisis , Acetaminofén/análisis , Adulto , Antieméticos/análisis , Compuestos de Azabiciclo/análisis , Citalopram/análisis , Femenino , Toxicología Forense , Cabello/crecimiento & desarrollo , Humanos , Metoclopramida/análisis , Morfina/análisis , Oxazepam/análisis , Piperazinas/análisis , Sertralina/análisis , Sumatriptán/análisis , Tramadol/análisisRESUMEN
Quantitative multicomponent analysis is considered an analytical goal to save time and cost in analysis. Hence, this work aimed to provide sensitive and selective UV-spectrophotometric, chemometric manipulation, and ultra-performance LC (UPLC) methods for the determination of well-known coformulated antiemetics used in pregnancy, namely pyridoxine HCl (PYR), meclozine HCl, and cyclizine. The developed UV-spectrophotometric methods are dual wavelength in ratio spectra and first derivative of the ratio spectra with which PYR was determined selectively at 290.8 nm, whereas the other drugs in a ternary mixture were determined from their ratio spectra using a spectrum of PYR as a divisor in 0.1 M HCl. An ecofriendly partial least-squares regression chemometric method was applied to raw UV absorbance data for the determination of the ternary mixture in a 218-355 nm range using a three-factor, three-level design with water as the green solvent. A gradient UPLC method was developed and successfully resolved the ternary mixture within 5 min. Different ratios of water (adjusted to pH 3 with phosphoric acid) and methanol were delivered at 0.5 mL/min as the mobile phase into a Hypersil Gold C18 column (50 × 2.1 mm, 1.9 µm). The developed methods were successfully applied to different pharmaceutical formulations containing the aforementioned drugs and validated according to the International Conference on Harmonization guidelines. The results obtained were reproducible and reliable and can be applied for routine analysis and QC in laboratories.
Asunto(s)
Antieméticos/análisis , Ciclizina/análisis , Meclizina/análisis , Calibración , Cromatografía Líquida de Alta Presión , Combinación de Medicamentos , Composición de Medicamentos , Análisis de los Mínimos Cuadrados , Piridoxina/análisis , Análisis de Regresión , Espectrofotometría UltravioletaRESUMEN
OBJECTIVE: This review was prepared to offer the most complete information about the use of ondansetron in parenteral admixtures with other drugs. METHOD: The search was done from September 2016 to April 2017 by using electronic databases Stabilis® and Micromedex® solutions, Medline/PubMed and Scholar Google searching publications about ondansetron stability in parenteral infusion when is administered by itself or with other medication. RESULTS: 49 studies are included with a total of 53 drugs. 15 drugs were found compatible administered with ondansetron in a clinical routine concentration range in intravenous administration. Also, four ternary blends were found compatible and another one was incompatible. Otherwise, 38 drugs were found incompatible. DISCUSSION: Compatibility of ondansetron offers a broad number of options to be used to avoid nausea and vomiting symptoms in patients with other concomitant medication.
Objetivo: Esta revisión ha sido preparada para recopilar toda la información referente a la estabilidad del ondansetrón en mezclas parenterales junto a otros fármacos.Método: La búsqueda fue realizada entre septiembre de 2016 y abril de 2017 empleando bases de datos electrónicas como Stabilis® y Micromedex® solutions, Medline/PubMed y Google Académico buscando publicaciones sobre la estabilidad del ondansetrón para infusión vía parenteral cuando es administrado en monoterapia o en una mezcla con otros fármacos.Resultados: En este trabajo han sido incluidos 49 artículos con un total de 53 fármacos. 15 fármacos han sido descritos como compatibles con ondansetrón en concentraciones habituales en la clínica práctica para administración intravenosa. Además, cuatro mezclas ternarias han sido descritas como compatibles y una como incompatible. Por otro lado, 38 fármacos han sido descritos como incompatibles para su administración con ondansetrón.Discusión: La compatibilidad del ondansetrón ofrece un amplio rango de opciones para evitar los síntomas de náuseas y vómitos en pacientes con otra medicación concomitante.
Asunto(s)
Antieméticos/análisis , Ondansetrón/análisis , Antieméticos/uso terapéutico , Combinación de Medicamentos , Estabilidad de Medicamentos , Humanos , Infusiones Parenterales , Náusea/prevención & control , Ondansetrón/uso terapéutico , Vómitos/prevención & controlRESUMEN
Despite advances in antiemetic therapy, chemotherapy-induced nausea and vomiting (CINV) still poses a significant burden to patients undergoing chemotherapy. Nausea, in particular, is still highly prevalent in this population. Ginger has been traditionally used as a folk remedy for gastrointestinal complaints and has been suggested as a viable adjuvant treatment for nausea and vomiting in the cancer context. Substantial research has revealed ginger to possess properties that could exert multiple beneficial effects on chemotherapy patients who experience nausea and vomiting. Bioactive compounds within the rhizome of ginger, particularly the gingerol and shogaol class of compounds, interact with several pathways that are directly implicated in CINV in addition to pathways that could play secondary roles by exacerbating symptoms. These properties include 5-HT3, substance P, and acetylcholine receptor antagonism; antiinflammatory properties; and modulation of cellular redox signaling, vasopressin release, gastrointestinal motility, and gastric emptying rate. This review outlines these proposed mechanisms by discussing the results of clinical, in vitro, and animal studies both within the chemotherapy context and in other relevant fields. The evidence presented in this review indicates that ginger possesses multiple properties that could be beneficial in reducing CINV.
Asunto(s)
Antieméticos/uso terapéutico , Antineoplásicos/efectos adversos , Modelos Biológicos , Náusea/prevención & control , Rizoma/química , Vómitos/prevención & control , Zingiber officinale/química , Animales , Antiinflamatorios no Esteroideos/análisis , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/uso terapéutico , Antieméticos/análisis , Antieméticos/química , Antioxidantes/análisis , Antioxidantes/química , Antioxidantes/uso terapéutico , Catecoles/análisis , Catecoles/metabolismo , Catecoles/uso terapéutico , Etnofarmacología , Alcoholes Grasos/análisis , Alcoholes Grasos/metabolismo , Alcoholes Grasos/uso terapéutico , Humanos , Náusea/inducido químicamente , Náusea/metabolismo , Náusea/fisiopatología , Vómitos/inducido químicamente , Vómitos/metabolismo , Vómitos/fisiopatologíaRESUMEN
INTRODUCTION: The aim of the study was to investigate the long-term stability of dexamethasone 10mg associated with alizapride 100mg or ondansetron 8mg in 100mL of 0.9% sodium chloride solution stored at 5±3°C. METHOD: Solutions of 0.9% sodium chloride 100mL in polyolefin bags (n=5) containing approximately dexamethasone (DEX) 10mg associated with alizapride (ALI) 100mg or ondansetron (OND) 8mg were prepared under aseptic conditions and stored about 30 days at 5±3°C. ALI, DEX and OND concentrations were measured by high-performance liquid chromatography (HPLC). Optic density measurement at different wavelengths, pH measurement and optic microscope observations were performed periodically during the storage. A forced degradation test with HCL 5M and NaOH 5M before and after heating at 100°C was also performed. Solutions were considered stable if the 95% one-sided lower confidence limit of the concentration remains superior to 90% of the initial concentration or 95% of the initial concentration when any signs of physical instability exist as recently recommend. RESULTS: The calibration was linear over the following range from 20 to 1.25mg/100mL for DEX, from 200 to 12.5mg/100mL for ALI and from 20 to 1.25mg/100mL for OND with a calculated correlation coefficient (r2) of 0.998, 0.999 and 0.999, respectively. The inter- and intra-assay precision was below 10% for both mixtures. All formulations were physically stable during the storage. The lower confidence limit of the concentration for these solutions remains superior to 90% of the initial concentration at this date as recommended by the Food and Drug Administration (FDA) until 30 days. CONCLUSION: The HPLC method is specific and reproducible and can easily be adopted for monitoring the quality control in the production of DEX-ALI and DEX-OND bags. Solutions of DEX-ALI and DEX-OND were physically and chemically stable for 30 days in polyolefin bags stored at 5±3°C and could therefore be prepared in advance.
Asunto(s)
Antieméticos/análisis , Dexametasona/análisis , Ondansetrón/análisis , Pirrolidinas/análisis , Combinación de Medicamentos , Estabilidad de Medicamentos , Almacenaje de Medicamentos , Soluciones Farmacéuticas , Polienos , Cloruro de SodioAsunto(s)
Antiasmáticos , Anticoagulantes , Antieméticos , Diarrea , Aprobación de Drogas , Adenosina Monofosfato/análogos & derivados , Adenosina Monofosfato/uso terapéutico , Aminopiridinas/análisis , Aminopiridinas/farmacología , Aminopiridinas/uso terapéutico , Antiasmáticos/análisis , Antiasmáticos/farmacología , Antiasmáticos/uso terapéutico , Anticuerpos Monoclonales Humanizados/análisis , Anticuerpos Monoclonales Humanizados/farmacología , Anticuerpos Monoclonales Humanizados/uso terapéutico , Anticoagulantes/análisis , Anticoagulantes/farmacología , Anticoagulantes/uso terapéutico , Antieméticos/análisis , Antieméticos/farmacología , Antieméticos/uso terapéutico , Benzodioxoles/análisis , Benzodioxoles/farmacología , Benzodioxoles/uso terapéutico , Colagogos y Coleréticos/análisis , Colagogos y Coleréticos/farmacología , Colagogos y Coleréticos/uso terapéutico , Regulador de Conductancia de Transmembrana de Fibrosis Quística/análisis , Regulador de Conductancia de Transmembrana de Fibrosis Quística/farmacología , Regulador de Conductancia de Transmembrana de Fibrosis Quística/uso terapéutico , Ácido Desoxicólico/análisis , Ácido Desoxicólico/farmacología , Ácido Desoxicólico/uso terapéutico , Diarrea/tratamiento farmacológico , Imidazoles/análisis , Imidazoles/farmacología , Imidazoles/uso terapéutico , Síndrome del Colon Irritable/fisiopatología , Compuestos de EspiroRESUMEN
Diphenidol hydrochloride (DPN), a nonphenothiazinic antiemetic agent used primarily in patients with Meniere disease and labyrinthopathies to treat vomiting and vertigo, is considered to be a relatively safe drug. Since it was first approved in the United States in 1967, this drug has been widely used in Latin America and Asia and has contributed to sporadic suicidal and accidental poisonings in mainland China and Taiwan. However, its toxic or lethal concentration ranges have not yet been determined. We report a case of a 23-year-old female who suffered from DPN poisoning that resulted in death. At autopsy, there were no typical pathological findings, except for cerebral edema with high acetylcholinesterase expression. Postmortem analysis of DPN revealed 45 µg/ml in heart blood, 39 µg/ml in femoral vein blood, 141 µg/g in the liver, and 53 mg in the gastric contents. These concentrations indicated that the cause of death was DPN poisoning. The circumstances indicated that the manner of death was suicide. We also present a retrospective study, in which we review and summarize the literature from 1998 to 2014 and describe 16 cases of poisoning, including information from autopsy reports and postmortem drug concentrations. In forensic practice, drug residues at the scene, patients with convulsions and disturbance of consciousness, and rapidly occurring deaths, should draw attention to the possibility of this drug. Toxicological analysis and the exclusion of other diseases may ultimately be used to confirm DPN poisoning.
Asunto(s)
Antieméticos/envenenamiento , Piperidinas/envenenamiento , Antieméticos/análisis , Antieméticos/química , Edema Encefálico/patología , Femenino , Contenido Digestivo/química , Humanos , Hígado/química , Estructura Molecular , Piperidinas/análisis , Piperidinas/química , Estudios Retrospectivos , Suicidio , Adulto JovenRESUMEN
Simultaneous determination of Dimenhydrinate (DIM) and Cinnarizine (CIN) binary mixture with simple procedures were applied. Three ratio manipulating spectrophotometric methods were proposed. Normalized spectrum was utilized as a divisor for simultaneous determination of both drugs with minimum manipulation steps. The proposed methods were simultaneous constant center (SCC), simultaneous derivative ratio spectrophotometry (S(1)DD) and ratio H-point standard addition method (RHPSAM). Peak amplitudes at isoabsorptive point in ratio spectra were measured for determination of total concentrations of DIM and CIN. For subsequent determination of DIM concentration, difference between peak amplitudes at 250 nm and 267 nm were used in SCC. While the peak amplitude at 275 nm of the first derivative ratio spectra were used in S(1)DD; then subtraction of DIM concentration from the total one provided the CIN concentration. The last RHPSAM was a dual wavelength method in which two calibrations were plotted at 220 nm and 230 nm. The coordinates of intersection point between the two calibration lines were corresponding to DIM and CIN concentrations. The proposed methods were successfully applied for combined dosage form analysis, Moreover statistical comparison between the proposed and reported spectrophotometric methods was applied.
Asunto(s)
Antieméticos/análisis , Cinarizina/análisis , Dimenhidrinato/análisis , Antagonistas de los Receptores Histamínicos H1/análisis , Espectrofotometría/métodos , Formas de Dosificación , Combinación de MedicamentosRESUMEN
This work was dedicated to the development of a simple and direct multivariate UV spectrophotometric method for the simultaneous determination of three antiemetic drugs (ondansetron, dexamethasone and aprepitant) in a new organogel formulation developed for their simultaneous transdermal administration. This method that does not require separation of the drugs and sophisticated instrument will permit to control quality of this new transdermal form both during the optimization step and for a further routine control of this preparation at the pharmacy department of the hospital. Hence, a partial least squares regression model using the spectral data record from 260 to 288 nm and 5 components, has firstly been validated thanks to the evaluation of the REP% (under 7.9%) and secondly using an accuracy profile approach (acceptance limit of ±10%). Thereby, the method allows the quantitation of the drugs in the ranges (5-15 mg L(-1)), (4-8 mg L(-1)) and (20-50 mg L(-1)) for ondansetron, dexamethasone and aprepitant, respectively. An HPLC/UV reference method has also been developed. Optimal separation (2.52Asunto(s)
Antieméticos/análisis
, Dexametasona/análisis
, Geles/química
, Morfolinas/análisis
, Ondansetrón/análisis
, Espectrofotometría Ultravioleta/métodos
, Administración Cutánea
, Antieméticos/administración & dosificación
, Aprepitant
, Cromatografía Líquida de Alta Presión/métodos
, Dexametasona/administración & dosificación
, Análisis de los Mínimos Cuadrados
, Límite de Detección
, Morfolinas/administración & dosificación
, Ondansetrón/administración & dosificación
RESUMEN
In the present work, an on-line dual focusing technique based on field-enhance sample injection (FASI) and dynamic pH junction (DypH) was developed for the analysis of two 5-hydroxy-tryptamine type 3 receptor (5-HT3) antagonists ondansetron (Ond) and tropisetron (Tro) by capillary electrophoresis with amperometric detection (CE-AD) system. By preparing the sample in a lower conductivity (FASI condition) and lower pH value (DypH condition) matrix relative to the background electrolyte (BGE) solution, a simple and effective dual focusing approach, FASI-DypH was achieved. In this stacking mode, a large amount of analytes could be electrokinetically injected into the capillary and stacked at the boundary of the sample and the BGE zone as a result of deprotonation and decrease in the electric field. Effects of separation, detection and FASI-DypH focusing conditions were investigated in detail. Under the optimum conditions, good separation for Ond and Tro was achieved within 8min. In comparison with the conventional CE-AD analysis method, the present dual focusing technique enabled the enhancement factors in terms of peak heights to reach 357-fold and 345-fold for Ond and Tro, respectively. The limits of detection (LODs) (S/N=3) for Ond and Tro were 2nM and 5nM, respectively. The intraday and interday repeatabilities (RSDs) were less than 4.5% and 2.9% for peak height and migration time, respectively. The proposed method was successfully applied for the analysis of Ond and Tro in human urine sample.
Asunto(s)
Antieméticos/análisis , Indoles/análisis , Ondansetrón/análisis , Antagonistas del Receptor de Serotonina 5-HT3/análisis , Antieméticos/orina , Electroforesis Capilar/métodos , Femenino , Humanos , Concentración de Iones de Hidrógeno , Indoles/orina , Límite de Detección , Ondansetrón/orina , Antagonistas del Receptor de Serotonina 5-HT3/orina , TropisetrónRESUMEN
Reproducibility of the tablet manufacturing process and control of its pharmaceutics properties depends on the optimization of formulation aspects and process parameters. Computer simulation such as Design of Experiments (DOE) can be used to scale up the production of this formulation, in particular for obtaining sustained-release tablets. Bromopride formulations are marketed in the form of extended-release pellets, which makes the product more expensive and difficult to manufacture. The aim of this study was to formulate new bromopride sustained release formulations as tablets, and to develop mathematical models to standardize the scale up of this formulation, controlling weight and hardness of the tablets during manufacture according to the USP 34th edition. DOE studies were conducted using Minitab(tm) software. Different excipient combinations were evaluated in order to produce bromopride sustained-release matrix tablets. In the scale-up study, data were collected and variations in tableting machine parameters were measured. Data were processed by Minitab(tm) software, generating mathematical equations used for prediction of powder compaction behavior, according to the settings of the tableting machine suitable for scale-up purposes. Bromopride matrix tablets with appropriate characteristics for sustained release were developed. The scale-up of the formulation with the most suitable sustained release profile was established by using mathematical models, indicating that the formulation can be a substitute for the pellets currently marketed.
A reprodutibilidade do processo de fabricação de comprimidos e o controle das suas propriedades farmacotécnicas depende da otimização dos aspectos de formulação e dos parâmetros de processo. O planejamento de experimentos como o Desenho de Experimentos (DOE) pode ser utilizado para acelerar a produção desta formulação, em particular, para a obtenção de comprimidos de liberação prolongada. Formulações de bromoprida são comercializadas sob a forma de péletes de liberação prolongada, o que torna o produto caro e de difícil fabricação. O objetivo deste estudo foi preparar novas formulações de bromoprida de liberação prolongada na forma de comprimidos e desenvolver modelos matemáticos visando ao escalonamento destas formulações, controlando o peso e a dureza dos comprimidos durante a fabricação, de acordo com a 34ª Edição da USP. Estudos de DOE foram realizados utilizando o software Minitab(tm). Diferentes combinações de excipientes foram avaliadas visando à obtenção dos comprimidos de liberação prolongada de bromoprida. No estudo de scale-up, coletaram-se e mediu-se a influência das variações nos parâmetros da máquina de compressão. Processaram-se os dados obtidos pelo software Minitab (tm), gerando equações matemáticas aptas para a previsão do comportamento de compactação do pó em escala industrial. Os comprimidos obtidos apresentavam características adequadas em termos de liberação sustentada, sendo a cinética de liberação estabelecida utilizando modelos matemáticos, indicando que esta formulação pode ser uma substituta aos péletes de bromoprida atualmente comercializados.
Asunto(s)
Comprimidos/análisis , Antieméticos/análisis , Proyectos de Investigación , Cinética , Escalas de PreparaciónRESUMEN
A micellar electrokinetic chromatography (MEKC) method was developed for the determination of three anti-vomiting drugs (aprepitant, dexamethasone and ondansetron) in pharmaceutical formulations. The method was optimized using a central composite design (CCD). Four main factors (borate buffer concentration, pH, methanol content and sodium dodecyl sulfate concentration) were optimized in order to obtain best resolutions and peak efficiencies in a minimum runtime. The separation was performed in a fused-silica capillary. After optimization, the background electrolyte consisted of a borate buffer (62.5mM, pH 8.75) containing sodium dodecyl sulfate (77.5mM) and methanol (3.75%). Under these conditions, a complete separation of each antiemetic drug and its respective internal standards was achieved in 38min. The method was validated with trueness values from 94.9 to 107.2% and precision results (repeatability and intermediate precision) lower than 5.9%. MEKC-UV was the first method allowing the separation of aprepitant, dexamethasone and ondansetron and was suitable for the quantitation of these three antiemetic drugs in organogel formulations. The rapid sample preparation coupled with an automated separation technique make this method convenient for quality control of extemporaneous magistral ready-to-use formulation.
Asunto(s)
Antieméticos/análisis , Cromatografía Capilar Electrocinética Micelar/normas , Dexametasona/análisis , Morfolinas/análisis , Ondansetrón/análisis , Antieméticos/química , Aprepitant , Química Farmacéutica , Dexametasona/química , Geles , Morfolinas/química , Ondansetrón/químicaRESUMEN
In 0.1 mol L(-1) HCl medium, antiemetic drugs (ATM), such as granisetron hydrochloride (GS) and tropisetron hydrochloride (TS), reacted with H(3)PW(12)O(40)·nH(2)O and formed 3:1 ion-association complex of [(ATM)(3)PW(12)O(40)], then self-aggregated into nanoparticles-[(ATM)(3)PW(12)O(40)](n) with an average size of 100 nm. The reaction resulted in the enhancement of resonance Rayleigh scattering (RRS) and the absorption spectra. The increments of scattering intensity (ΔI(RRS)) and the change of absorbance (ΔA) were both directly proportional to the concentrations of ATM in certain ranges. Accordingly, two new RRS and spectrophotometric methods were proposed for ATM detection. The detection limits (3σ) of GS and TS were 3.2 ng mL(-1) and 4.0 ng mL(-1)(RRS method), 112.5 ng mL(-1) and 100.0 ng mL(-1)(spectrophotometric method). These two methods were applied to determine GS in orally disintegrating tablets and the results were in good agreement with the official method. The ground-state geometries and electronic structures of GS and TS were optimized by the hybrid density functional theory (DFT) method and the shape of [(ATM)(3)PW(12)O(40)](n) was characterized by atomic force microscopy (AFM). Take the RRS method with higher sensitivity as an example, the reaction mechanism and the reasons for enhancement of scattering were discussed.
Asunto(s)
Antieméticos/análisis , Granisetrón/análisis , Indoles/análisis , Ácidos Fosfóricos/química , Espectrometría de Fluorescencia/métodos , Compuestos de Tungsteno/química , Luz , Límite de Detección , Modelos Moleculares , Nanopartículas/química , Dispersión de Radiación , Espectrofotometría Ultravioleta/métodos , TropisetrónRESUMEN
OBJECTIVE: Aprepitant (APR) is a water insoluble drug approved for the treatment of chemotherapy induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV). The innovator Emend® is a formulation incorporating drug nanoparticles with good bioavailability (~67%). The objective of the current work was to evaluate the feasibility of formulating a cyclodextrin complex of APR with enhanced solubility/dissolution rate and concomitantly bioavailability. METHODS: The complex was prepared using two approaches: kneading and slurry method. The formulated complex was evaluated using DSC, XRPD and FT-IR studies. RESULTS: DSC, XRPD and FT-IR studies confirmed the interaction of ß-cyclodextrin with APR indicating formation of a true complex wherein the drug was encapsulated in the cyclodextrin cavity (inclusion phenomenon). In addition to inclusion complexation, non inclusion phenomenon viz., interaction among hydroxyl groups of cyclodextrin and APR was also observed. The saturation solubility and dissolution rate of drug complex was higher than that of aprepitant API. The rate (C(max)) and extent of absorption (AUC) of APR from the complex were found to be comparable to that of Emend® (Reference product). CONCLUSION: These studies established that cyclodextrin complexation may provide another viable and cost effective option for enhancing solubility and bioavailability of APR.